Viewing Study NCT02529956


Ignite Creation Date: 2025-12-24 @ 11:38 PM
Ignite Modification Date: 2026-02-23 @ 6:27 AM
Study NCT ID: NCT02529956
Status: COMPLETED
Last Update Posted: 2015-08-20
First Post: 2015-08-19
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of UCB4940 in Patients With Psoriasis
Sponsor: UCB Celltech
Organization:

Study Overview

Official Title: A Randomized, Subject-blind, Investigator-blind, Placebo-controlled, Single-dose, Dose-escalating Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of UCB4940 in Patients With Mild to Moderate Psoriasis
Status: COMPLETED
Status Verified Date: 2015-08
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: To evaluate the safety of UCB4940 administered by iv infusion of a single ascending dose in subjects with mild to moderate plaque psoriasis.
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
2012-002086-35 EUDRACT_NUMBER None View